Logo image of HRTX

HERON THERAPEUTICS INC (HRTX) Stock Fundamental Analysis

NASDAQ:HRTX - Nasdaq - US4277461020 - Common Stock - Currency: USD

2.27  +0.07 (+3.18%)

Premarket: 2.26 -0.01 (-0.44%)

Fundamental Rating

2

HRTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. HRTX may be in some trouble as it scores bad on both profitability and health. HRTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HRTX had negative earnings in the past year.
HRTX had a negative operating cash flow in the past year.
In the past 5 years HRTX always reported negative net income.
HRTX had a negative operating cash flow in each of the past 5 years.
HRTX Yearly Net Income VS EBIT VS OCF VS FCFHRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

HRTX's Return On Assets of -5.82% is amongst the best of the industry. HRTX outperforms 88.56% of its industry peers.
Industry RankSector Rank
ROA -5.82%
ROE N/A
ROIC N/A
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HRTX Yearly ROA, ROE, ROICHRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Gross Margin of HRTX (73.21%) is better than 82.75% of its industry peers.
In the last couple of years the Gross Margin of HRTX has grown nicely.
HRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
HRTX Yearly Profit, Operating, Gross MarginsHRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HRTX has more shares outstanding
HRTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HRTX has an improved debt to assets ratio.
HRTX Yearly Shares OutstandingHRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
HRTX Yearly Total Debt VS Total AssetsHRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -9.69, we must say that HRTX is in the distress zone and has some risk of bankruptcy.
HRTX's Altman-Z score of -9.69 is on the low side compared to the rest of the industry. HRTX is outperformed by 73.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.69
ROIC/WACCN/A
WACC9.38%
HRTX Yearly LT Debt VS Equity VS FCFHRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.29 indicates that HRTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.29, HRTX is doing worse than 72.71% of the companies in the same industry.
HRTX has a Quick Ratio of 1.70. This is a normal value and indicates that HRTX is financially healthy and should not expect problems in meeting its short term obligations.
HRTX has a Quick ratio of 1.70. This is in the lower half of the industry: HRTX underperforms 78.70% of its industry peers.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 1.7
HRTX Yearly Current Assets VS Current LiabilitesHRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.53% over the past year.
HRTX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.57%.
Measured over the past years, HRTX shows a decrease in Revenue. The Revenue has been decreasing by -0.24% on average per year.
EPS 1Y (TTM)89.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.57%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%19.13%

3.2 Future

HRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.05% yearly.
HRTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.25% yearly.
EPS Next Y58.44%
EPS Next 2Y77.01%
EPS Next 3Y61.47%
EPS Next 5Y45.05%
Revenue Next Year12.28%
Revenue Next 2Y14.02%
Revenue Next 3Y13.77%
Revenue Next 5Y13.25%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HRTX Yearly Revenue VS EstimatesHRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
HRTX Yearly EPS VS EstimatesHRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.
Also next year HRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HRTX Price Earnings VS Forward Price EarningsHRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HRTX Per share dataHRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

HRTX's earnings are expected to grow with 61.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y77.01%
EPS Next 3Y61.47%

More info and screens

0

5. Dividend

5.1 Amount

HRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HERON THERAPEUTICS INC

NASDAQ:HRTX (4/24/2025, 8:15:37 PM)

Premarket: 2.26 -0.01 (-0.44%)

2.27

+0.07 (+3.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners76.1%
Inst Owner Change-0.02%
Ins Owners0.63%
Ins Owner Change10.41%
Market Cap345.79M
Analysts84.44
Price Target4.59 (102.2%)
Short Float %21.22%
Short Ratio17.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.64%
Min EPS beat(2)11.76%
Max EPS beat(2)173.52%
EPS beat(4)3
Avg EPS beat(4)54.11%
Min EPS beat(4)-47.06%
Max EPS beat(4)173.52%
EPS beat(8)5
Avg EPS beat(8)30.01%
EPS beat(12)7
Avg EPS beat(12)20.5%
EPS beat(16)10
Avg EPS beat(16)16.4%
Revenue beat(2)1
Avg Revenue beat(2)-2.95%
Min Revenue beat(2)-12.91%
Max Revenue beat(2)7%
Revenue beat(4)2
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-12.91%
Max Revenue beat(4)7%
Revenue beat(8)3
Avg Revenue beat(8)-0.7%
Revenue beat(12)6
Avg Revenue beat(12)0.91%
Revenue beat(16)6
Avg Revenue beat(16)-4.39%
PT rev (1m)-25%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-22.23%
EPS NY rev (3m)-22.23%
Revenue NQ rev (1m)0.9%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.95
BVpS-0.22
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.21%
FCFM N/A
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.46%
Cap/Sales 1.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 1.7
Altman-Z -9.69
F-Score4
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)61.69%
Cap/Depr(5y)104.8%
Cap/Sales(3y)1.37%
Cap/Sales(5y)3.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.57%
EPS Next Y58.44%
EPS Next 2Y77.01%
EPS Next 3Y61.47%
EPS Next 5Y45.05%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%19.13%
Revenue Next Year12.28%
Revenue Next 2Y14.02%
Revenue Next 3Y13.77%
Revenue Next 5Y13.25%
EBIT growth 1Y89.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.68%
OCF growth 3YN/A
OCF growth 5YN/A